TriangleDefactinib (NCT06369259)
Defactinib trial for Advanced Colorectal Cancer (NCT06369259). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic colorectal adenocarcinoma after chemotherapy and anti-EGFR treatment that initially controlled disease. Before anti-EGFR treatment, KRAS, NRAS, EGFR-ectodomain and BRAF-V600E must test wild-type.
The idea: combine oral avutometinib and defactinib with cetuximab infusions. These drugs block RAF/MEK, FAK and EGFR growth signals, respectively. Early groups establish an avutometinib dose; later patients receive the selected dose. Researchers assess tumor response and safety. Prior ERK, MEK or BRAF inhibitors exclude participation.
This phase 2 study plans 33 patients. Christine Parseghian leads MD Anderson's recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.